Contra-indicated in patients with evidence of vitamin D toxicity or hypercalcemia.
- TRADE NAME: Zemplar (AbbVie)
- INDICATIONS: Secondary hyperparathyroidism associated with renal failure
- CLASS: Vitamin D receptor agonist
- HALF-LIFE: 4–7 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Bile acid sequestrants, Cardiac glycosides, Conivaptan, Danazol, Darunavir, Delavirdine, Digitalis (with overdose of paricalcitol), Digoxin, Ergocalciferol, Indinavir, Ketoconazole, Orlistat, Orlistat, Strong CYP3A4 inhibitors, Sucralfate, Telithromycin, Thiazide diuretics, Tocilizumab, Voriconazole
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of paricalcitol in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 03/13/2024
